Clinical Trial: Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome

This study is currently recruiting patients.

Sponsored by:	National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)

Purpose

RATIONALE: The identification of gene mutations in individuals who have or are at risk for von Hippel-Lindau syndrome may allow doctors to better determine the genetic processes involved in the development of cancer.

PURPOSE: Genetic study to identify gene mutations in participants who have von Hippel-Lindau syndrome or are at risk for developing von Hippel-Lindau syndrome.

Condition	Treatment or Intervention
Renal Cell Cancer von Hippel-Lindau Syndrome	Procedure: genetic analysis Procedure: mutation analysis

Study Type: Interventional
Study Design: Diagnostic

Official Title: Genetic Study of Mutations in Participants Previously Enrolled in NCI-99-C-0053 Who Have von Hippel-Lindau (VHL) Syndrome or Who Are at Risk for VHL Syndrome

Further Study Details:

OBJECTIVES:

Obtain laboratory identification and confirmation of research results for gene mutations in participants previously enrolled in NCI-99-C-0053 who have von Hippel-Lindau (VHL) syndrome or who are at risk for VHL syndrome.
Determine genotype status in these participants.

OUTLINE: Participants submit a blood or buccal sample for genetic mutation analysis. Participants may receive genetic counseling and/or the results of genetic testing, if desired.

PROJECTED ACCRUAL: A maximum of 260 participants will be accrued for this study.

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both

Criteria

DISEASE CHARACTERISTICS:

Prior enrollment in the von Hippel-Lindau (VHL) Syndrome Epidemiology Study NCI-99-C-0053
Meets 1 of the following criteria:
Diagnosis of VHL syndrome
At risk of VHL syndrome
Family member of patient with VHL syndrome
VHL syndrome genotype is not known

PATIENT CHARACTERISTICS: Age

Adult

Performance status

Not specified

Life expectancy

Not specified

Hematopoietic

Not specified

Hepatic

Not specified

Renal

Not specified

PRIOR CONCURRENT THERAPY: Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

Not specified

Radiotherapy

Not specified

Surgery

Not specified

Location and Contact Information

Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, 20892-1182, United States; Recruiting

Patient Recruitment 888-NCI-1937

Study chairs or principal investigators

William Marston Linehan, MD, Study Chair, National Cancer Institute (NCI)

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers: CDR0000302478; NCI-03-C-0148
Record last reviewed: December 2003
Record first received: January 9, 2004
ClinicalTrials.gov Identifier: NCT00075348
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-17

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services